Assembly Biosciences (NASDAQ:ASMB) is a clinical-stage biotechnology company dedicated to developing transformative therapies for patients with viral and microbiome-driven diseases. Since its founding in 2011, the company has built a diversified pipeline that includes novel hepatitis B virus (HBV) capsid inhibitors and core modulators designed to achieve functional cure, as well as microbiome-based therapeutics that harness precision modulation of gut ecosystems. Assembly’s research and development efforts leverage proprietary platforms to identify and optimize small molecules and biologics, advancing candidates through preclinical studies and regulatory filings.
The company’s lead programs target chronic HBV infection, an area of significant medical need. Its capsid assembly modulator candidates have demonstrated potent antiviral activity in Phase II clinical trials, with ongoing studies evaluating combination regimens aimed at reducing viral antigens and restoring host immune responses. In parallel, Assembly Biosciences is advancing a microbiome platform that employs state-of-the-art genomic and analytical tools to develop live biotherapeutic products for conditions such as Clostridioides difficile infection and inflammatory bowel diseases. These programs are designed to reshape the microbiome with precision-engineered communities of microorganisms, offering potential alternatives to conventional small-molecule treatments.
Headquartered in Plymouth Meeting, Pennsylvania, Assembly Biosciences conducts global clinical trials across North America, Europe and Asia, collaborating with leading academic institutions and strategic partners to accelerate development and broaden access. The company completed its initial public offering in 2015 and is traded on the NASDAQ under the symbol ASMB. Assembly maintains research and manufacturing partnerships with several pharmaceutical organizations, enhancing its ability to scale operations and navigate complex regulatory environments.
Under the leadership of Founder and Chief Executive Officer Dr. David A. Pinkerton, the company has assembled a management team with deep expertise in virology, microbiology and clinical development. Supported by a board of directors and scientific advisory panels, Assembly Biosciences continues to advance its mission of delivering innovative therapies that address unmet needs in viral and microbiome-related diseases, with the ultimate goal of improving patient outcomes worldwide.
